Breast cancer is defined as out of
control growth of cells in the breast which have the ability to form a
tumor or lump. These lumps or tumors in the breast are easily detectable
through an X-ray. Breast cancer can form in the duct, nipple, glands,
or other tissues. The most common types of breast cancer are invasive
lobular carcinoma, invasive ductal carcinoma, ductal carcinoma in situ,
triple negative breast cancer, metastatic breast cancer, and less common
being lymphomas or sarcomas and inflammatory breast cancer.
Breast cancer is one of the most common
cancers among woman globally and a major cause of mortality. Therefore,
early detection is needed for these diseases. Breast cancer is more
prevalent in the industrialized countries due to modernized lifestyle;
however, the rate of incidence is expected to rise in developing
countries.
According to the WHO, in 2012, round 1.7
million new cases of breast cancer were diagnosed globally. According to
the American Cancer Society, breast cancer accounts for 1 in 8 cancers
diagnosed in women in the U.S. Symptoms of breast cancer may or may not
appear in women. Hence, regular screening is necessary to prevent the
malignancy. Breast cancer screening is a regular examination to detect
breast cancer. Early detection could ensure timely treatment of
patients, thereby reducing the mortality rate. Breast cancer screening
generally involves mammography, MRI scan, or ultrasound. Mammography is
considered to be the best screening test for the detection of breast
cancer.
A rise in the standard of living and
educational opportunities for women had resulted in late first pregnancy
with limited lactation period indirectly leading to fluctuating hormone
levels and high risk of breast cancer. Probability of breast cancer
increases with age. Hence, rise in geriatric population is a major
factor for increase in incidence of breast cancer.
Rise in incidence of breast cancer,
growing awareness about breast cancer screening tests, government
initiatives for breast cancer screening programs, technical advancements
in breast imaging technologies, implementation of national level
programs by the government for early diagnosis are the major factors
driving the market.
Based on diagnostic test type, the global
breast cance
r screening tests market can be segmented into blood marker
tests, imaging test, genetic test, and immunohistochemistry test.
Imaging test is the most commonly used test for the screening of breast
cancer. The segment can be further divided into mammography, MRI
screening test, molecular breast imaging test, PET scan, and ultrasound.
Mammography is the most common test used for the detection of breast
cancer. Genetic test can be sub-segmented into fluorescence in situ
hybridization and HER gene test. In most developed countries,
mammography is included in the breast screening program making it the
most popular breast cancer screening test.
In terms of end-user, the global breast
screening tests market can be segmented into hospitals, diagnostic
centers, cancer institutes, and research laboratories. National breast
cancer screening awareness programs and awareness about genetic transfer
of breast cancer boost the growth of the diagnostic centers segment.
In terms of region, the global breast
cancer screening market can be segmented into North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. Countries
such as United States, Germany, United Kingdom, Japan and China capture
the maximum share for the population with higher probability of breast
cancer. In 2016, these countries accounted for over 60% share of the
global North America is anticipated to hold major market share, as 70%
of women in the U.S. undergo mammography. Germany is likely to dominate
the market in Europe, due to advanced health care infrastructure and
government supported screening programs. Availability of screening
services in private health care and diagnostic centers is expected to
drive the market in developing countries such as India.
Key players in the global breast cancer
screening tests market are A&G Pharmaceutical, Inc., Biocrates Life
Sciences AG, Metabolomic Technologies, Inc., Myriad Genetics, Siemens
Healthcare Diagnostics, Inc., OncoCyte Corporation, POC Medical Systems,
Inc., Hologic, Inc., Provista Diagnostics, Inc., and BioTime, Inc.
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment